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ABSTRACT 
Objective: Bosentan presents challenges with regard to low and variable oral bioavailability due to its poor aqueous solubility and poor dissolution in 
gastric fluid. Solid dispersion has been used as the solubility enhancement technique due to its ability to develop suitable system with improved 
solubility and dissolution rate. Methods: Solid dispersions of bosentan were prepared by using novel techniques like solvent controlled coprecipitation, 
fusion and nanoprecipitation. Polymers with different ionic characteristics like Eudragit® EPO (cationic), Eudragit® L 100 55 (anionic) and Povidone K 
30 (non-ionic) were employed at three different ratios of 1:1, 1:2 and 1:3 to prepare the solid dispersions of weakly basic bosentan.  Dissolution study in 
buffers corresponding to different physiologically relevant pH was performed to understand the effectiveness of the technique and effect of the polymer. 
Additionally, samples were subjected for X-ray powder diffraction study to understand the nature of the drug in solid state in the solid dispersion 
systems. Results: It was observed that irrespective of the pH of the dissolution media, the dissolution rate of the solid dispersions of BOS prepared with 
Eudragit® L 100 55 are higher than that of pure drug and the solid dispersions prepared with the other polymers i.e. Eudragit® EPO and Povidone K 30, 
which is attributed to the weakly basic nature of bosentan. The diffractograms show decrease in the crystallinity of bosentan  in the solid dispersions. 
Conclusion: The combination of solid dispersion technology with supersaturable systems appears to hold promise for improving dissolution and 
bioavailability of poorly soluble drugs. The selection of polymers that can inhibit crystallization of the drug in a supersaturated state becomes the key 
factor for an effective formulation. The present work is an attempt in this direction.  
KEYWORDS: Solid Dispersion, Super Saturable systems, Insoluble drugs. 
 
INTRODUCTION 
Water insolubility has always been a key obstacle in 
pharmaceutical formulations, affecting formulation stability and drug 
bioavailability. In the pharmaceutical industry, there is general 
consensus that poorly water-soluble drug candidates are becoming 
more prevalent [1]. It is estimated that approximately 40% of active 
substances which are poorly soluble in water are being identified 
through different combinatorial screening programs and high 
throughput screening [2, 3]. In the process of absorption of a drug 
candidate with reasonable membrane permeability, the rate-limiting 
step is the drug dissolution step. A compound that is poorly soluble is 
defined as the one dissolving in less than 1 part per 1000 parts of water 
and when water-solubility is less than 1µg/mL, which is often the case 
for contemporary drug candidates. For such drugs, the oral 
bioavailability from conventional formulations may be unacceptable. 
Many formulation strategies have been reported to improve 
the solubility and bioavailability of poorly-soluble compounds. 
However, when routine solubility enhancing techniques like co-solvent 
addition, pH modification, heat application, particle size reduction etc. 
fail to resolve solubility issues; some advanced formulation strategies 
are approached to improve the solubility of poorly soluble drugs. These  
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include complexation with cyclodextrins [4, 5], polymeric 
nanoarchitecture [6], self-emulsifying drug delivery system [7], emulsions 
and microemulsion, nano suspensions, micellar solubilization and solid 
dispersion [8]. 
The formulation development of poorly soluble drugs by solid 
dispersion technology utilizing different polymeric carrier has been 
widely researched over the past four decades for solubility and related 
bioavailability enhancement. In-spite of the active research till date, 
there has not been much marketed product based on solid dispersion 
technology. The main reason for this being stability and scale up 
problems associated with this method, as reported by several authors [9]. 
Nonetheless, solid dispersion technique is known to be an effective 
approach to keep drugs stable in the solid state, thereby improving the 
dissolution rate and oral absorption by inhibiting reprecipitation and/or 
recrystallization in supersaturated system. In solid dispersion, the drug 
is present in the carrier matrix either in molecularly distributed form, in 
the form of amorphous aggregates or, small crystalline or, partially 
crystalline form. The amorphous state is reported to have more 
solubility as compared to crystalline state [8-10]. All these forms account 
to have rapid drug dissolution of poorly soluble drugs leading to a 
supersaturated state. The stabilization of this supersaturated state by 
preventing reprecipitation of the drug appears to be the key to improve 
oral absorption. 
Bosentan (BOS) chemically named as (4-tert-butyl-N-[6-(2-
hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(pyrimidin-2-yl)pyrimidin-4-
yl]benzene-1-sulfonamide) is a non-peptide human endothelin-I 
receptor antagonist which is recommended for the treatment of 
pulmonary arterial hypertension [11]. It is classified as BCS class-II drug 
demonstrating approximately 50% absolute bioavailability which might 
be due to poor aqueous solubility (1.0 mg/100 mL) and dissolution, 
resulting in its low therapeutic outcome [12]. 
The present work is an attempt to prepare solid dispersions 
of bosentan with an objective to improve its dissolution. Rapid onset of 
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action is desirable to provide fast relief in the treatment of pulmonary 
arterial hypertension. Therefore, it is necessary to enhance the aqueous 
solubility and dissolution rate of BOS to obtain faster onset of action, 
minimize the variability in absorption and improve its overall oral 
bioavailability. 
MATERIALS AND METHODS 
Materials: 
Bosentan (BOS) was received from Natco Pharma Limited, 
Hyderabad, India. BOS is practically water insoluble compound with a 
melting point around 104.9◦C. The polymers: poly(methacrylic acid, 
ethyl acrylate) marketed under the trade name Eudragit® L 100 55 and 
poly(butyl methacrylate, (2-dimethylaminoethyl) methacrylate, methyl 
methacrylate) marketed under the trade name Eudragit® EPO were 
purchased from Evonik Industries whereas, Povidone K30 was supplied 
by DKSH India Pvt. Ltd. All the excipients were used as received. All 
other ingredients used were of pharmaceutical grade and solvents used 
were of HPLC grade. Water used in this study was purified by a Milli-Q 
Synthesis A10 system (Millipore, Billerica, MA) unless otherwise 
mentioned. 
Methods: 
Solubility parameter calculation: 
The solubility parameter calculation was carried out by in-
silico molecular modelling approach based on molecular dynamics. It 
aims to estimate the solubility for binary combinations of BOS with 
commonly used polymers. Solubility parameters using Van Krevelen 
methods, of both drug as well as the polymers were calculated in order 
to determine the theoretical drug/polymer miscibility [13]. 
Preparation of solid dispersions of BOS: 
The techniques used for the preparation of the solid 
dispersions are fusion technique, solvent controlled coprecipitation 
technique and nanoprecipitation technique. In all the techniques, solid 
dispersions of BOS were prepared using three different polymers, 
Eudragit® L 100 55 (anionic), Eudragit® EPO (cationic) and Povidone K 
30 (non-ionic). The ratio of drug to polymer was 1:1, 1:2 and 1:3. 
Fusion technique: Required quantity of BOS and the respective 
polymers were mixed thoroughly in a mortar and pestle and weighed 
into a stainless steel container and heated initially to 80°C on oil bath 
and stirred continuously using a stainless steel rod until the blend 
softens and melts. The final temperature was about 160°C.  The soft and 
molten mass was subjected for sudden cooling over an ice bath and then 
allowed to cool to room temperature (25°C±3°C). The solidified 
dispersions were milled approximately after 1 hour using a mixer 
grinder (Maple). The prepared samples were stored at 25°C in a 
desiccator. The resulting dried solid dispersion samples were 
characterized and analysed.   
Solvent controlled coprecipitation technique: BOS and the polymer 
were dissolved in N, N- Dimethyl acetamide (DMA). The solution was 
introduced at ambient temperature into the respective antisolvent kept 
under stirring at 2500 to 3000 rpm under a laboratory stirrer by 
spraying through a spray nozzle 1mm in diameter with a spray rate of 
12 gm per minute.  The DMA-antisolvent phase ratio was maintained at 
1:12 (w/w). The resulting precipitate was separated by filtration 
through two layer of nylon filter cloth (200 mesh followed by 400 mesh) 
under vacuum. The resulting precipitate was washed with 9.0 liters of 
the respective antisolvents. The wet precipitate mass was dried in tray 
dryer at 50°C for 9 hours. The resulting dried solid dispersion samples 
were characterized and analysed.  The antisolvents used were 0.01 N 
HCl for Eudragit® L 100 55 containing preparation, 0.067 M Phosphate 
Buffer, pH 6.8 for Eudragit® EPO containing preparation and water for 
Povidone K 30 containing preparation.  
Nanoprecipitation technique: BOS was dissolved in ethanol (98%). 
Eudragit® L 100 55 was dissolved in 0.067 M Phosphate Buffer, pH 6.8, 
Eudragit® EPO was dissolved in 0.1 N HCl and Povidone K 30 was 
dissolved in water. The drug solution was added to the polymer solution 
by spraying at a rate of 12 gm/min under stirring at 500 to 700 rpm. 
This resulted in a colloidal dispersion of BOS. The mean size and size 
distribution of dispersions was determined by photon correlation 
spectroscopy using Zetasizer ZS 90 (Malvern Instruments, Malvern, UK). 
Each sample was diluted to a suitable concentration with filtered Milli-Q 
water. Analysis was performed at 25oC with an angle of detection of 90o. 
The mean size was directly obtained from the instrument. The drug 
polymer complex in the colloidal dispersions was further precipitated 
by addition of the corresponding antisolvent. The antisolvent used was 
0.01N HCl for Eudragit® L 100 55 containing preparations, 0.067 M 
Phosphate Buffer, pH 6.8 for Eudragit® EPO containing preparations and 
water with few crystals of sodium chloride (0.05% w/v) for Povidone K 
30 containing preparations. The resultant wet mass was separated by 
centrifugation process (Kubota®, 7780 Japan) at 7000 rpm for 7 min. 
The wet precipitate were further separated by filtration under vacuum 
through two layer of nylon filter cloth (200 mesh followed by 400 
mesh). The wet precipitate was dried in tray dryer at 60°C. The resulting 
dried solid dispersion samples were characterized and analysed.   
Characterization of the solid dispersions: 
The solid dispersions were evaluated for angle of repose, bulk 
and tap density. Carr’s Index values and Hausner’s ratio were calculated 
from bulk and tap density data. The moisture content of the solid 
dispersions was analyzed by Karl Fischer (K.F) titration method. The 
porosity (%) was determined by liquid displacement method. 
BOS content in all the samples of solid dispersions was 
analyzed by UV spectrophotometry. Required quantity of solid 
dispersion was dispersed in 5 mL of ethanol. The suspension was 
sonicated in an ultrasonic bath for 15 minutes and then centrifuged for 
15 minutes at 2500 rpm. The supernatant was filtered through Nylon 
0.45µm filter (Millipore Millex-HN). The filtrate was suitably diluted and 
the absorbance was read at 266 nm. A standard graph was plotted by 
measuring the absorbance of different concentrations of BOS in ethanol 
(2-12 mcg/mL). The correlation coefficient (R2) of the regression line 
was 0.9997. The drug concentration in the test solution was obtained 
from regression equation. 
X-ray Powder Diffractometry (XRPD): 
XRPD was performed with an X-ray diffraction system 
(PANalytical, X’Pert PRO diffractometer) using the detector pixcel. The 
powders were exposed to Cu-Kα radiation source at 45kV and 40 mA. 
Diffractions patterns were obtained in 2θ at a range of 2-80o using 
0.02oC step size and 10°/min scan speed. The measurement was done 
with the application of X’Pert Highscore. 
In-vitro dissolution studies of the solid dispersions: 
The in-vitro drug dissolution study of the solid dispersions 
were performed using an 8 station USP 23 dissolution testing apparatus, 
Type II (Electrolab, India, model TDT-08L). Sodium lauryl sulfate, 1% 
w/v solution in 0.1N HCl and 0.067 M Phosphate Buffer, pH 6.8 (± 0.1) 
were used as dissolution media. Solid dispersions equivalent to 20 mg of 
BOS was dispersed in 450 mL of dissolution media. The temperature 
was maintained at 37°C ± 0.5°C and the dispersion was stirred at 50 
RPM. At predetermined time intervals 5 mL of samples were withdrawn, 
filtered through Nylon 0.45µm filter (Millipore Millex-HN) and analysed 
spectrophotometrically at 265 nm. At each time of withdrawal, 5 mL of 
fresh corresponding medium was replaced. The cumulative amount of 
drug release was calculated from the regression line obtained for 
standard samples in 0.1N HCl as well as 0.067 M Phosphate Buffer, pH 
6.8 (± 0.1).  
Statistical analysis: 
The dissolution profile obtained for the solid dispersions 
were statistically analysed and compared using fit factors described by 
Moore and Falnner [14], adopted by the Food and Drug Administration 
guidance for dissolution testing. Briefly, fit factors are model 
independent methods that directly compare the difference between 
percent drug dissolved per unit time for a test and a reference product. 
The statistical analysis was carried out to evaluate the dissolution 
profile by the calculation of similarity and dissimilarity factor. The 
similarity factor (f2) was defined by Food and Drug Administration 
(FDA) as the ‘logarithmic’ reciprocal square root transformation of one 
plus the mean squared difference in percent dissolved between the test 
and references release profiles. Dissimilarity or, difference factor (f1) 
describes the relative error between two dissolution profiles. It 
approximates the percent error between the curves. 
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RESULTS AND DISCUSSION 
Results: 
Solubility parameter calculation [Hansen solubility parameters (δ)]:  
Compounds with similar values of δ are likely to be miscible. 
It was demonstrated that compounds with a Δδ < 7.0 (MPa)1/2 were 
likely to be miscible. When the Δδ > 10(MPa)1/2, the compounds were 
likely to be immiscible. The small difference between the calculated 
solubility parameters of the polymers and BOS indicated that BOS is 
likely to be miscible with Eudragit® L 100 55 (data not shown). 
Solid dispersions of BOS by fusion technique: 
The solid dispersion samples were prepared with the binary 
composition of BOS to the polymers in a ratio 1:1, 1:2 and 1:3 by fusion 
technique utilizing the utilizing Eudragit® L 100 55, Eudragit® EPO and 
Povidone K 30 as the carrier agent. This technique also yielded 
reasonably good dry powders. The recovery of powders from the 
process was more than 75%. The BOS content of the solid dispersions 
ranged from 90-100% of the anticipated amount and the moisture 
content for the solid dispersions lies between 1.40 to 2.20 (% w/w). The 
moisture content of BOS was observed to be 3.17%. The results revealed 
reasonable compressibility and flowability characteristics. The results 
are recorded in table 1. 
Solid dispersions of BOS by solvent controlled coprecipitation 
technique: 
The solid dispersion samples were prepared with the binary 
composition of BOS to the polymers in a ratio 1:1, 1:2 and 1:3 by solvent 
controlled coprecipitation technique utilizing same polymers as by the 
above technique as the carrier agent. This technique yielded reasonably 
good dry powders. The recovery of powders from the process was more 
than 60%. Higher polymer concentration even resulted about 90% 
recovery. The BOS content of the solid dispersions ranged from 90-
100% of the anticipated amount and the moisture content lies between 
1.90 and 3.02 (% w/w). The results revealed reasonable compressibility 
and flowability characteristics. The results are recorded in table 1. 
Solid dispersions of BOS by nanoprecipitation technique: 
The solid dispersion samples were prepared with the binary 
composition of BOS to the polymers in a ratio 1:1, 1:2 and 1:3 by 
nanoprecipitation technique utilizing the same polymers as by the 
above technique. This technique yielded reasonably good dry powders. 
The recovery of powders from the process was in between 50% to 
around 75%. The BOS content of the solid dispersions ranged from 90-
100% of the anticipated amount and the moisture content for BOS and 
the solid dispersions was below 3.0 (% w/w). The results revealed 
reasonable compressibility and flowability characteristics. The results 
are recorded in table 1. 
Characterization of solid dispersions: 
The details of flow and compression characteristics of BOS 
and different solid dispersions samples are recorded in table 1. The 
solid dispersions showed comparable micromeritic, flow and 
compressible properties. The angle of repose for the drug powder BOS is 
obtained as 40°. For solid dispersions it ranged from 24° to 34°. The 
solid dispersions (in particular fusion technique samples) showed 
better compressibility indices than that of BOS which may be due to the 
hybrid denser particles of drug inside the polymer matrix. The particles 
of the solid dispersions prepared by all the above mentioned techniques 
have reasonable porous nature. However, the porosity of the solid 
dispersions prepared by solvent controlled coprecipitation technique 
and nano-precipitation technique was higher. The presence of moisture 
is a crucial characteristic for the solid dispersions as they could induce 
instability. The solid dispersion samples prepared by fusion technique 
have moisture content less than 2.2% w/v which may be due to the 
application of heat during the processing. The solid dispersions 
prepared from solvent controlled coprecipitation technique and 
nanoprecipitation technique possess higher amount of moisture (< 
3.5%).  
The size of the dispersions corresponding to the solid 
dispersions by nanoprecipitation technique are observed and recorded 
in table 2 and the average size ranged from 50 nm to 600 nm. However, 
the polydispersibility index was high. The increase in polymer 
concentration led to higher particle size in the preparations 
corresponding to all the three polymers. 
X-ray Powder Diffractometry (XRPD): 
The extent of crystallinity affects dissolution of drugs. 
Generally, amorphous or, metastable form will dissolve faster because of 
its higher internal energy and greater molecular motion compared to 
crystalline materials. Crystallinity was determined by comparing some 
representative peak heights in diffraction patterns of the solid 
dispersions with those of pure drug. The XRPD pattern of BOS, placebo 
and the solid dispersions by different techniques is presented in Figure 
1. The presence of numerous distinct peaks in the diffractrogram of BOS 
reveal the crystalline nature of BOS with characteristic diffraction peaks 
appearing at 9.20, 18.54 and 18.67.  
The solid dispersions prepared by solvent controlled 
coprecipitation technique suggest that the sample containing lower 
concentration of Eudragit®  EPO (BCPE1) and Eudragit®  L 100 55 
(BCPL1) have shown the characteristic peaks of BOS in the 
diffractograms although the intensity is very low indicating partial 
crystalline nature. The peak intensities are significant in solid 
dispersions with Povidone K 30 at both the ratio 1:1 and 1:3. Solid 
dispersions with the other two polymers Eudragit® EPO and Eudragit® L 
100 55, have shown amorphous solid dispersions in presence of higher 
concentration of polymers (BHME3 and BHML3). 
The solid dispersions prepared by nano precipitation 
technique, have shown the presence of characteristic peak of BOS in the 
solid dispersion samples corresponding to all the three polymers. 
However, the intensity was lower in the case of preparations 
corresponding to Eudragit® L 100 55. 
In solid dispersions prepared by fusion technique both the 
preparations with Eudragit® L 100 55 and Povidone K 30 yielded 
amorphous dispersions even at 1:1 ratio. At lower ratio of 1:1 Eudragit® 
EPO shows partially crystalline BOS. Thus, fusion technique generally 
yields an amorphous dispersion whereas, nanoprecipitation gives 
crystalline dispersion. Coprecipitation on the other hand gives 
amorphous dispersion when the polymer concentration is high. The 
nature of the drug in the solid dispersion also appears to depend on the 
nature of polymers as Povidone K 30 even in higher concentration 
yielded crystalline dispersions. 
In-vitro dissolution studies of the solid dispersions: 
The powder dissolution data reported in Figure 2 shows that 
the dissolution profile of BOS as such was the lowest of all, with no more 
than 10% dissolved within 2 hours in both the media. The presence of 
SLS in the dissolution media also could not improve the dissolution BOS. 
In comparison to this, the release of BOS was improved from different 
solid dispersions in the two dissolution media.  
Solid dispersions prepared with Eudragit® L 100 55 have 
shown higher dissolution in pH 6.8 phosphate buffer irrespective of the 
technique used. For the solid dispersions prepared by all the three 
techniques, it reached near complete dissolution in 90 minutes. The 
dissolution appears to be higher and faster at higher polymer 
concentration. For formulation prepared with Eudragit® EPO, the extent 
of dissolution was much lower in all the three techniques. However, 
amongst the three techniques, nanoprecipitation method produced 
dissolution of upto 30% in 60 min at higher ratio of polymer. The solid 
dispersions prepared using solvent controlled coprecipitation yielded 
lowest dissolution level of about 19% in 60 min. The lower rate of 
dissolution with preparations corresponding to Eudragit® EPO is 
expected at pH 6.8 since the polymer dissolves in acidic media. Thus, it 
should resist the drug release at pH 6.8. 
In contrast to this, neutral polymer Povidone K 30 has also 
shown lower rate of dissolution. The highest percent dissolution was 
about 39%. Further, with both the above polymers, the dissolution 
dropped significantly after reaching a peak indicating drug 
precipitation. On the contrary, preparations made with Eudragit® L 100 
55 did not show such a drop.  
In the acidic medium 0.1 N HCl containing SLS, drug as such 
showed similar extent of low dissolution. The dissolution reached about 
11% in 120 min. In this medium, preparations made with Eudragit® EPO 
showed maximum dissolution of about 32% in 60 minutes irrespective 
of the method of preparation used. Thereafter, the dissolution profile 
shows significant drop up to 120 min indicating reprecipitation of the 
drug. 
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In the case of preparations made from neutral polymer 
Povidone K 30, similar trend is observed in the solid dispersions made 
by all the three techniques. The highest dissolution value observed is 
36% with solvent controlled coprecipitation technique, it was 29% by 
fusion method and about 54% in the preparation with nanoprecipitation 
technique. However, reprecipitation of the drug was evident in all the 
samples prepared with all the three techniques. 
For preparation made with Eudragit® L 100 55, the extent of 
dissolution was found to be the highest in the dispersions made with all 
the three techniques. The drug polymer ratio had a significant influence 
on dissolution. Further, no drop in the dissolution could be observed up 
to 120 min any of the samples except for the samples prepared by 
nanoprecipitation method at 1:1 drug polymer ratio (BNPL1). 
High drug dissolution with Eudragit® L 100 55 is surprising in 
the acidic media since Eudragit® L 100 55 dissolves only at higher pH 
and is expected to hold the drug and prevent its release at low pH when 
the polymer does not dissolve.  
Higher dissolution of the drug in acid media is attributable to 
the porosity of the solid dispersion and the presence of SLS in the 
medium. Coupled to this, the solubilization effect of Eudragit® L 100 55 
towards the drug BOS because of its acidic functional group might aid in 
holding the drug in solid dispersion and then release it under acidic 
conditions in a controlled manner. Irrespective of the media used, a rank 
order relation between BOS products and their dissolution was evident.  
BOS<SDs of BOS (Eudragit® EPO) <SDs of BOS (Povidone K 30) < SDs of 
BOS (Eudragit® L 100 55) 
Statistical analysis: 
Analysis of the similarity and difference factors (table 3) 
suggested that f1 values of test samples is not close to zero and nor it lies 
between 0-15. This states that there is a substantial difference between 
the dissolution profiles of the test samples with that of controls. 
Considering arbitrarily, as f1 ≥10 or f2 ≤ 50, the curve was considered to 
be substantially different from that of the controls. Therefore, the solid 
dispersions prepared with Eudragit® L 100 55 (test samples) with 
different techniques have an edge and significantly different and 
improved dissolution profile than that of the controls in both the 
dissolution media irrespective of the pH of the media. 
 
Table No. 1: Physico-Chemical characterization and micromeritics properties of solid dispersions of bosentan 
NA: Not applicable; MC: Moisture content, BD: Bulk density; TD: Tapped density, CI: Carr’s compressibility index, HR: Hausner’s ratio, AR: Angle of repose, P: Porosity 
Table No. 2: Characteristics of different preparations of from bosentan in Milli Q water in nanoprecipitation technique 
S. No. Polymers Ratio Sample Code Average size (nm) Polydispersity index 
1 Eudragit® L 
100 55 
R 1:1 BNPL1 53.77 0.441 
R 1:2 BNPL2 511.8 0.338 
R 1:3 BNPL3 558.6 0.52 
2 Eudragit® 
EPO 
R 1:1 BNPE1 182.5 0.186 
R 1:2 BNPE2 199.4 0.193 
R 1:3 BNPE3 228.4 0.278 
3 Povidone K 
30 
R 1:1 BNPP1 183.1 0.524 
R 1:2 BNPP2 254.8 0.794 
R 1:3 BNPP3 479.2 0.198 
S. No. Techniqu
es 
Polymer Ratio Code MC (%) Assay (%) BD (g/mL) TD (g/mL) CI (%) HR P (%) AR (°) 
1 NA NA NA BOS 3.17 99.80 0.21 0.26 19.08 1.24 37.36 40.00 
2 Fusion Eudragit L 
100 55 
(Anionic) 
R 1:1 BHML1 1.50 96.48 0.36 0.45 21.43 1.27 54.91 25.00 
3 R 1:2 BHML2 1.70 95.27 0.42 0.50 16.67 1.20 50.89 25.00 
4 R 1:3 BHML3 1.85 98.91 0.42 0.50 16.67 1.20 49.16 24.00 
5 Eudragit 
EPO 
(Cationic) 
R 1:1 BHME1 1.40 96.48 0.33 0.42 20.00 1.25 59.35 25.00 
6 R 1:2 BHME2 1.45 96.61 0.36 0.42 14.56 1.17 58.11 25.00 
7 R 1:3 BHME3 2.00 97.58 0.38 0.50 23.08 1.30 53.92 25.00 
8 Povidone 
K 30 
(Nonionic) 
R 1:1 BHMP1 1.60 90.18 0.36 0.42 14.29 1.17 54.86 26.00 
9 R 1:2 BHMP2 1.80 90.30 0.37 0.45 19.26 1.24 54.45 25.00 
10 R 1:3 BHMP3 2.21 97.70 0.42 0.50 16.67 1.20 49.16 27.00 
11 Solvent 
controlled 
coprecipita
tion 
Eudragit L 
100 55 
(Anionic) 
R 1:1 BCPL1 2.61 96.73 0.25 0.31 20.00 1.25 68.63 30.00 
12 R 1:2 BCPL2 2.29 95.27 0.25 0.29 15.00 1.18 70.40 32.00 
13 R 1:3 BCPL3 2.28 96.85 0.24 0.30 20.39 1.26 70.50 32.00 
14 Eudragit 
EPO 
(Cationic) 
R 1:1 BCPE1 2.35 93.45 0.24 0.31 23.81 1.31 70.99 33.00 
15 R 1:2 BCPE2 1.90 93.82 0.24 0.29 19.05 1.24 71.85 33.00 
16 R 1:3 BCPE3 2.72 97.33 0.24 0.29 19.05 1.24 71.42 34.00 
17 Povidone 
K 30 
(Nonionic) 
R 1:1 BCPP1 2.78 92.00 0.23 0.31 27.27 1.38 71.45 30.00 
18 R 1:2 BCPP2 2.87 93.58 0.23 0.31 27.27 1.38 71.89 30.00 
19 R 1:3 BCPP3 3.02 97.82 0.25 0.31 20.00 1.25 69.52 30.00 
20 Nanopreci
pitation  
Eudragit L 
100 55 
(Anionic) 
R 1:1 BNPL1 2.50 93.45 0.25 0.31 19.00 1.23 68.44 32.00 
21 R 1:2 BNPL2 2.80 94.79 0.28 0.31 10.00 1.11 67.26 32.00 
22 R 1:3 BNPL3 2.85 98.30 0.28 0.31 10.56 1.12 66.11 32.00 
23 Eudragit 
EPO 
(Cationic) 
R 1:1 BNPE1 2.70 93.70 0.24 0.30 20.48 1.26 70.96 33.00 
24 R 1:2 BNPE2 2.75 96.61 0.27 0.30 10.81 1.12 68.20 32.00 
25 R 1:3 BNPE3 2.71 97.58 0.27 0.31 11.41 1.13 67.45 31.00 
26 Povidone 
K 30 
(Nonionic) 
R 1:1 BNPP1 2.60 95.88 0.25 0.31 20.00 1.25 68.40 32.00 
27 R 1:2 BNPP2 2.84 95.27 0.28 0.31 11.11 1.13 65.52 33.00 
28 R 1:3 BNPP3 2.90 96.00 0.28 0.32 12.50 1.14 66.11 32.00 
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Table No. 3: Statistical treatment to the dissolution profile of respective solid dispersions of BOS with Eudragit® L 100 55 prepared by 
different techniques 
  f1 f2 
Dissolution medium BOS BCPE3 BCPP3 BOS BCPE3 BCPP3 
0.1 N HCl 88.18 58.02 42.47 15.52 20.12 24.87 
pH 6.8 phosphate buffer 94.94 84.57 71.57 4.31 6.70 10.25 
  BOS BHME3 BHMP3 BOS BHME3 BHMP3 
0.1 N HCl 91.69 69.01 70.91 7.85 12.39 13.14 
pH 6.8 phosphate buffer 94.41 81.89 73.52 6.07 9.21 11.55 
  BOS BNPE3 BNPP3 BOS BNPE3 BNPP3 
0.1 N HCl 92.04 73.96 54.56 7.85 11.19 14.12 
pH 6.8 phosphate buffer 94.52 73.77 71.13 6.08 10.82 12.63 
 
 
A 
 
B 
 
C 
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Fig. 1: X-ray powder diffraction pattern summarizing the comparative diffractogram of BOS, placebo and different solid dispersions 
prepared by solvent controlled coprecipitation technique from (A) Eudragit® EPO (BCPE1 and BCPE3), (B) Eudragit® L 100 55 (BCPL1and 
BCPL3), (C) Povidone K 30 (BCPP1and BCPP3); by fusion technique from  (D) Eudragit® EPO (BHME1and BHME3), (E) Eudragit® L 100 55 
(BHML1and BHML3), (F) Povidone K 30 (BHMP1and BHMP3); by nanoprecipitation technique from (G) Eudragit® EPO (BNPE1and BNPE3), 
(H) Eudragit® L 100 55 (BNPL1and BNPL3) and (I) Povidone K 30 (BNPP1and BNPP3). 
Discussion: 
It is evident that the dissolution rate of the solid dispersions 
of BOS prepared with Eudragit® L 100 55 are higher than that of pure 
drug and the solid dispersions prepared with the other polymers i.e. 
Eudragit® EPO and Povidone K 30. The possible elucidations of the 
increased dissolution rate of solid dispersions have been proposed by 
Craig and Ford [15, 16], which encompasses reduction of drug crystallite 
size, a solubilization effect of the carrier, absence of aggregation of drug 
crystallites, improved wettability and dispersibility of the drug, 
dissolution of the drug in the hydrophilic carrier, conversion of the drug 
to the amorphous state and finally the combination of the above 
mentioned mechanisms. We observed hike in the drug release from the 
solid dispersions in the dissolution media which may be attributed to 
any of the above mechanisms or, combination thereof. The ultimate 
success of a solid dispersion is determined by its performance in 
dissolution after oral administration. The general strategy behind 
almost all solubilization technologies is the so called “spring-and-
parachute” concept [17]. For a solid dispersion, this means that the drug 
should first dissolve along with the soluble polymer matrix to create a 
supersaturated solution (“the spring”) after which supersaturation is 
maintained long enough for drug absorption (“the parachute”) to take 
place.  
Generally, solid dispersions generate a supersaturated drug 
solution when exposed to the aqueous environment of the 
gastrointestinal tract. Drugs in this state have a tendency to precipitate 
rapidly before being absorbed resulting in reduced bioavailability. A 
variety of polymer excipients have been evaluated for their ability to 
prolong the supersaturation and inhibit drug precipitation [18]. The 
researchers have reported different polymers like hydroxypropyl 
methylcellulose (HPMC) and hydroxypropylmethylcellulose acetate 
succinate (HPMCAS) and vinyl polymers such as poly (vinylpyrrolidone) 
(PVP) and poly(vinylpyrrolidone-co-vinyl acetate) (PVPVA) which are 
employed not only as carriers for solid dispersions but are also meant 
for inhibiting drug precipitation. In the present study, we have 
employed polymers with different ionic nature like Eudragit® L 100 55 
(anionic), Eudragit® EPO (cationic) and Povidone K 30 (non-ionic) to 
evaluate the effect of the polymers in maintaining a supersaturated drug 
concentration in the dissolution medium.    
  It was observed that the solid dispersions of BOS with 
Eudragit® L 100 55 show better release profile without any significant 
drop in the drug release. The increase in the dissolution may be 
attributed to the interaction of drug with the polymer or, changing the 
properties of the medium or both [19, 20] or, suppressing the nucleation 
process [21] or, adsorbing on the surface of crystals to block the access of 
solute molecules (“the poisoning effect”) thus preventing or retarding 
crystal growth [22, 23]. It is evident from the in silico studies that 
Eudragit® L 100 55 interacts with BOS. The interaction between BOS 
and Eudragit® L 100 55 may be due to the hydrogen bond formation 
and/or hydrophobic interactions. 
The hydrogen-bond acceptors in BOS may be interacting with 
Eudragit® L 100 55 alluding about the effectiveness of Eudragit® L 100 
55 in inhibiting nucleation and recrystallization [24-26] in a concentration 
dependent manner. The process of delaying of nucleation and inhibition 
of recrystallization may be not only due to the increase in the nucleation 
activation energy but also reduce crystal growth [27-29]. Many researchers 
have discussed different characteristic features of drug and polymer in 
the hydrogen bonding interaction. The lipophilicity of the polymers, 
rigidity of the polymers, adsorption onto the crystal surface resulting in 
steric hindrance and few other factors have been discussed [30-37]. The 
interaction via hydrogen bonding between the carboxyl group of the 
anionic methacrylate co-polymer and -NH group of BOS was the basis 
for the interaction strength. This interaction has been well depicted by 
the solubility parameter showing that Δδ< 7.0 (MPa)1/2 implying of 
better miscibility of the drug in the polymer. However, it should also be 
noted that the solubility of the drug in the polymer is not enough to 
prevent the recrystallization and improvement in the drug release.   
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Dissolution profiles of solid dispersions with Eudragit®L 100 
55 showed an increase in the dissolution rate of BOS with respect to the 
drug by itself which could be due to the acidic nature of the polymer. It 
is also clear that increasing the weight fraction of BOS in the solid 
dispersions did not affect noticeably the dissolution rate of the solid 
dispersions. The dissolution mechanism of solid dispersion with 
Eudragit® L 100 55 might be predominantly diffusion-controlled, and 
presumably the high viscosity of this carrier in stagnate layer is the 
main factor to control the dissolution rate. The supersaturation of 
bosentan was effectively prolonged in the presence of Eudragit® L 100 
55. 
 
Fig. 2: Cumulative release of BOS from solid dispersions (A) solid dispersions by solvent controlled coprecipitation technology, 
(B) solid dispersions by fusion technique (C) solid dispersions by nanoprecipitation technique in 0.067 M Phosphate Buffer, pH 6.8 + 1% 
w/v SLS; (D) solid dispersions by solvent controlled coprecipitation technology, (E) solid dispersions by fusion technique (F) solid 
dispersions by nanoprecipitation technique in 0.1 N HCl + 1% w/v SLS: Each value represents the mean ± SD, (n=3). 
 
In general, drug release from the solid dispersions occur in 
different possible ways like a) dissolution of drug and polymer in the 
solid dispersion in a rapid manner then subsequently undergo 
absorption and precipitation in the presence of polymer and 
endogenous compounds such as bile acids, phospholipids and mucin as 
described for low drug loaded solid dispersions and b) it is also 
explained that during this dissolution process, various structures may 
form including free drug (the major species, if not the only species, 
being absorbed, so its concentration is what matters for absorption), 
drugs in bile salt/phospholipid micelles, amorphous drug 
nanoprecipitates with polymers, and possibly drug nanocrystals 
stabilized with polymers, all of which are in dynamic exchange with 
each other [38].  
We have attempted to achieve pH-independent release of BOS 
from hydrophilic matrices by incorporation of polymers of different 
ionic characteristics to compare the release behaviour. The solid 
dispersions prepared with Eudragit® L 100 55 (anionic) are presumed 
to lower the release in the acidic environment by forming an insoluble 
mass which may act as barrier to drug diffusion and enhance release in a 
high pH environment. However, we observed that in spite of having low 
permeability of Eudragit® L 100 55 to 0.1N HCl significant improved 
release behaviour was observed for the solid dispersions with Eudragit® 
L 100 55 than the solid dispersions prepared from other polymers. BOS 
molecules could have been solubilized due to the acidity of the polymers 
and got released completely. Further, porosity of solid dispersion and 
presence of SLS could have aided the drug release under different 
conditions. In the case of nanoprecipitation, the drug is in crystalline 
form but the release is high. It is known that nanosize affects the 
solubility and the dissolution. Thus, this form also appears to aid in 
creation of supersaturated state that is subsequently stabilized by the 
polymer.  
We have attempted three novel techniques like solvent 
controlled coprecipitation, fusion and nanoprecipitation for preparing 
the solid dispersions of BOS. In spite of having differences in the 
preparation procedure and other physico chemical properties, it was 
observed that judicious choice of polymer and technique are 
prerequisite of preparing solid dispersion formulation development of 
any drug. Drug-polymer interaction through hydrogen bonding or, any 
other electrostatic interaction play a get role in achieving drug-polymer 
miscibility and maintenance of super saturation in the gastric milieu for 
a period.  
It is also evident that the presence of crystalline peaks in the 
diffractograms of different solid dispersions is not affecting the 
dissolution. The solid dispersions prepared with different 
concentrations of Eudragit® L 100 55 by nanoprecipitation technique 
have shown better release profile than the solid dispersions prepared 
from Eudragit® EPO with the same technique in spite of the absence of 
the peaks in the diffractogram of BNPE3. Although the solid dispersions 
prepared by the same technique with Eudragit® L 100 55 have the peaks 
in the diffractogram, the release profile was significantly better than the 
other solid dispersions.  
Porosity provides pathways for the penetration of fluid into 
the powder through capillary action and resulted in rupture of inter-
particulate bonds causing the powder to break and the change in the 
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morphological form contributed to the dissolution velocity 
enhancement. The solid dispersions prepared from the solvent 
controlled coprecipitation technology and nanoprecipitation technique 
have shown a porosity of 65 to 70%. However, the solid dispersions 
obtained from fusion technique exhibited lower porosity of 49 to 55% 
which is however higher than BOS itself (37%) and is attributed to the 
molten stringent polymer layer on the particles. 
The release behaviour indicate solubilization is related to the 
ionic nature of the polymer. The polymer-specific properties of 
Eudragit® L 100 55 prolonged supersaturation by increasing media 
viscosity and interaction with BOS are attributing for the inhibiting 
behaviour against crystallization. 
CONCLUSION 
As an increasing proportion of drugs undergoing 
development are poorly water-soluble, solubilization technologies have 
become an essential feature in bringing them successfully to market. 
The solid dispersion is one such technology which in recent years has 
led to the approval of a large number of products, suggesting it is now 
the preferred technology for drug solubilization. These results 
emphasize that mechanisms of supersaturation could differ significantly 
depending on the specific drug-polymer combination. 
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